The International IVF Initiative - i3


International IVF Initiative



Tuesday 28th September, 2021. 3PM EST/ 8PM GMT / 9PM CET


Alejandro Chavez-Badiola (IVF 2.0)
David Sable MD


"Scientia Potentia Est.” -Matt Pettit.  A lecture sponsored by IMT Matcher

Staying in the driver seat of your lab and moving forward-Dr. Dimitri Consten
A lecture sponsored by XiltiX

Management of IVF; Electronic applications to the rescue-Ms Unika Alexander

Closing remarks-David Sable MD


Matt Pettit, Head of innovation and product specialist at
IMT International.
Matt is responsible for the provision of cryopreservation systems to animal breeding programmes and for the development and implementation of Matcher, an electronic witnessing and quality management system for IVF clinics and donor banks.
After gaining a degree in Biology at the University of Wales in 1990, Matt worked in Research and Development at the cattle breeding company, Genus Plc., specialising in Bovine and Equine sperm processing, cryopreservation, and semen evaluation techniques. After establishing a stallion semen freezing unit at Australasia’s largest standard-bred ranch, ‘Alabar Bloodstock’, Matt took up the post of Manager of Research and Development at the Duke of Westminster’s bovine sperm sexing facility, ‘Cogent’. Cogent were the first company in the world to be issued a licence to sex sperm by flow cytometry and achieved the world’s first commercially sexed offspring in 2001, using techniques now widely adopted by the global dairy and beef industries.

Matt joined IMT International in 2005 and plays an integral role in the continuous development of IMT products in line with customer’s requirements and assists with sales and marketing of products through to implementation of products and training.

Matt’s professional qualifications include: BSc Biology; Quality Manager for ISO9001; Manager for Development of technology for ART (Cryopreservation and Quality Management); Speaker on error prevention, quality and risk management in IVF laboratories from theory to practice; e-Learning; and advisor on the GaMP (Good automated manufacturing practice) framework for system validation.


Dr. Dimitri Consten is a clinical embryologist and laboratory manager at the Elisabeth-TweeSteden hospital in Tilburg. He studied Biology at the Utrecht University and received his PhD at the same university, working in the field of Comparative Endocrinology and Developmental Biology. After a post-doctoral research track at the Hubrecht Institute he joined the IVF lab of the Elisabeth-TweeSteden hospital in 2004. Since 2015 he is laboratory manager of the IVF lab. His main interests are quality control and embryo development.
Presentation sponsored by XiltriX - Protecting Your Science


Unika has a master’s degree in biomedical science (Embryology and Andrology), from Eastern Virginia Medical School.
She is a Clinical Laboratory Scientist licensed by American Society of Clinical Pathology with 10 years of experience in reproductive medicine.
She previously worked with California Cryobank as a Branch Manager, Laboratory Operations Manager and Tissue Bank Director but currently working with Northwell Health Fertility as the Clinical Laboratory Operations Manager.


Since 2018, Founder and Scientific Director at IVF 2.0 UK LTD, a biotech company, committed to the advancement of reproductive medicine.
Founder and Chief Medical Officer at the New Hope Fertility Mexico since 2009
Appointed as Proffessor and Research Coordinator, Clinical Sciences Division, Health Sciences, Universidad de Guadalajara, Mexico (2007)
Training in Reproductive Medicine at the Hewitt Centre for Reproductive Medicine, Liverpool Women’s Hospital (2005-2007)
Entered in the British General Medical Council (GMC) Registry in 2005
Received the Highly Skilled Specialist Sponsorship by The British Council (2004)
Training in Obstetrics and Gynaecology at Hospital Civil, Guadalajara. Appointed as Chief Resident in Obstetrics and Gynaecology twice in this period (2000-2004).
Graduated with Honours from Medical School at Universidad de Guadalajara, Mexico (1998)


David Sable MD directs healthcare and life science investing for the Special Situations Funds and is portfolio manager for the Special Situations Life Sciences Fund and Life Sciences Innovation Venture Capital funds.

After graduating from the Wharton and Penn Med, he trained in Ob Gyn at New York Presbyterian, and in reproductive endocrinology at Brigham and Women's Hospital. He co-founded and served as director of IRMS at Saint Barnabas Medical Center, was founder of Assisted Reproductive Medical Technologies, acquired by Saint Barnabas in 1999, and co-founder of Reprogenetics, acquired by Cooper Surgical in 2015.

Dr. Sable is an adjunct in the department of biology at Columbia University. He serves on boards for for Hamilton Thorne, MedAnswers, and Celmatix, and TMRW Life Sciences. He previously served as a board member for Ohana Biosciences, Genenews Inc, RESOLVE, Progyny and Ovascience. He has written for the Newark Star-Ledger, Yoga Journal, Xconomy, Genetic Engineering and Biotechnology News, the Timmerman Report, Wharton Magazine, Forbes and Medium.

Close (esc)


Members get free stuff and can stay up to date with the latest sessions from I3.

Become a Member

Age verification

By clicking enter you are verifying that you are old enough to consume alcohol.


Shopping Cart

Your cart is currently empty.
Shop now